Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s What Hedge Funds Think About Iovance Biotherapeutics, Inc. (IOVA)

During the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by nearly 7 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. only 298 S&P 500 constituents were among the 500 most popular stocks among hedge funds), and we have seen data that shows those funds paring back their overall exposure. Those funds cutting positions in small-caps is one reason why volatility has increased. In the following paragraphs, we take a closer look at what hedge funds and prominent investors think of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and see how the stock is affected by the recent hedge fund activity.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shareholders have witnessed a decrease in hedge fund interest recently. Our calculations also showed that iova isn’t among the 30 most popular stocks among hedge funds.

So, why do we pay attention to hedge fund sentiment before making any investment decisions? Our research has shown that hedge funds’ small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the market by 32 percentage points since May 2014 through March 12, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter. Even if you aren’t comfortable with shorting stocks, you should at least avoid initiating long positions in our short portfolio.

Broadfin Kevin Kotler

Let’s analyze the key hedge fund action encompassing Iovance Biotherapeutics, Inc. (NASDAQ:IOVA).

What does the smart money think about Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)?

Heading into the first quarter of 2019, a total of 22 of the hedge funds tracked by Insider Monkey were long this stock, a change of -19% from one quarter earlier. By comparison, 18 hedge funds held shares or bullish call options in IOVA a year ago. With hedge funds’ capital changing hands, there exists an “upper tier” of key hedge fund managers who were adding to their stakes significantly (or already accumulated large positions).

No of Hedge Funds with IOVA Positions

Among these funds, Perceptive Advisors held the most valuable stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), which was worth $108.3 million at the end of the fourth quarter. On the second spot was venBio Select Advisor which amassed $90.8 million worth of shares. Moreover, Broadfin Capital, Farallon Capital, and Great Point Partners were also bullish on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), allocating a large percentage of their portfolios to this stock.

Due to the fact that Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has witnessed bearish sentiment from the entirety of the hedge funds we track, it’s easy to see that there were a few fund managers that elected to cut their positions entirely heading into Q3. Interestingly, John Osterweis’s Osterweis Capital Management dumped the largest stake of all the hedgies watched by Insider Monkey, totaling about $5.1 million in stock. James A. Silverman’s fund, Opaleye Management, also dropped its stock, about $3.7 million worth. These moves are important to note, as total hedge fund interest fell by 5 funds heading into Q3.

Let’s go over hedge fund activity in other stocks similar to Iovance Biotherapeutics, Inc. (NASDAQ:IOVA). These stocks are Electronics For Imaging, Inc. (NASDAQ:EFII), OceanFirst Financial Corp. (NASDAQ:OCFC), SemGroup Corp (NYSE:SEMG), and Editas Medicine, Inc. (NASDAQ:EDIT). This group of stocks’ market values resemble IOVA’s market value.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
EFII 12 137901 -2
OCFC 12 57674 -3
SEMG 12 34576 5
EDIT 18 105423 1
Average 13.5 83894 0.25

View table here if you experience formatting issues.

As you can see these stocks had an average of 13.5 hedge funds with bullish positions and the average amount invested in these stocks was $84 million. That figure was $542 million in IOVA’s case. Editas Medicine, Inc. (NASDAQ:EDIT) is the most popular stock in this table. On the other hand Electronics For Imaging, Inc. (NASDAQ:EFII) is the least popular one with only 12 bullish hedge fund positions. Compared to these stocks Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is more popular among hedge funds. Our calculations showed that top 15 most popular stocks) among hedge funds returned 24.2% through April 22nd and outperformed the S&P 500 ETF (SPY) by more than 7 percentage points. Hedge funds were also right about betting on IOVA as the stock returned 24.9% and outperformed the market by an even larger margin. Hedge funds were clearly right about piling into this stock relative to other stocks with similar market capitalizations.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.